bioRxivMicrobiologyPreprint
Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents
Shashikanta SauiD, Rohit Kumar, Arnab RoyiD, Puja Kumari AgniveshiD, Pallavi SahaiD, Harshada Anil BhaleraoiD, Rajesh SontiiD, Deepak Kumar SharmaiD, Nitin Pal KaliaiD
Abstract
Mycobacterium tuberculosis possesses a flexible metabolic system helping it to survive inside the host. The type II NADH dehydrogenase, composed of Ndh and NdhA, essential for bacilli, is a promising drug target. Based on ATP depletion values, two quinoline scaffolds were shortlisted after screening of a library of drug like molecules. Structurally, both 64-9C and 64-9D carry ester moieties at the 5- and 8-positions of the quinoline core, respectively. Ease to re-synthesise 64-9D resulted in synthesis of a focused library of compounds, with MIC values of 0.25-4 g/mL, consistent with ATP depletion. These compounds exhibited bactericidal activity against non-replicating mycobacteria, and showed potent efficacy against multidrug-resistant isolates. Altered, intracellular NADH/NAD+ ratio and reduced respiration was indicative of oxidative phosphorylation inhibition. Inhibition of the purified recombinant NDH protein uncompetitively, SNPs in gene encoding NDH-2 for selected one step mutants and, molecular modelling of 4FQN and 2FQN validated NDH-2 as a target for these compounds. The derivative 2FQN exhibited dose-dependent bactericidal efficacy in mice, underscoring the potential of the series as a promising anti-tuberculosis candidates.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure of mycobacterial NDH-2 bound to a 2-mercapto-quinazolinone inhibitor
Yingke Liang, Stephanie A. Bueler, … John L. Rubinstein·Journal of Medicinal ChemistryPeer-reviewed·Mar 21, 2025
- Discovery of a novel chemotype targeting Mycobacterium tuberculosis cytochrome bd through rapid screening and structural elucidation
Tijn T. van der Velden, Asad Halimi, … Lars J. C. Jeuken·bioRxiv·May 22, 2026
- Synthetic lethality of Mycobacterium tuberculosis NADH dehydrogenases is due to impaired NADH oxidation
- Repurposing Novobiocin for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyltransferase (Rv2421c)
Ruben E.A. Cloete, Mohd Shahbaaz, … Alan Gilbert Christoffels·bioRxiv·Jul 30, 2020
- Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis
Arnab Roy, Satish Kushwah, … Nitin Pal Kalia·bioRxiv·Nov 23, 2025
- InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis
L. Flint, A. Korkegian, T. Parish·bioRxiv·Aug 19, 2020